NMT Set To Study Next-Generation BioStar Tissue-Based PFO Closure Device
This article was originally published in The Gray Sheet
Executive Summary
NMT Medical plans to begin human clinical studies of its next-generation, bio-resorbable patent foramen ovale (PFO) closure device,BioStar, in the second quarter of this year
You may also be interested in...
NMT Medical
Firm receives a grant from the National Institutes of Health to conduct a Phase I trial for its BioTrek bioactive patent foramen ovale closure device at the Dartmouth-Hitchcock Medical Center. The product joinsBioStar as NMT's second bioabsorbable closure technology. NMT is counting on the ongoing UK BEST study to support a CE mark for BioStar in the first half of the year (1"The Gray Sheet" March 7, 2005, p. 29)...
NMT Medical
Firm receives a grant from the National Institutes of Health to conduct a Phase I trial for its BioTrek bioactive patent foramen ovale closure device at the Dartmouth-Hitchcock Medical Center. The product joinsBioStar as NMT's second bioabsorbable closure technology. NMT is counting on the ongoing UK BEST study to support a CE mark for BioStar in the first half of the year (1"The Gray Sheet" March 7, 2005, p. 29)...
NMT completes enrollment in UK
The 60-patient, multi-center BEST study (BioSTAR Evaluation STudy) has finished enrolling patients, the firm announces Nov. 29. The trial, which is designed to support a CE mark, is evaluating the BioStar bioabsorbable collagen matrix technology's ability to close the patent foramen ovale, which could treat migraine headaches, recurrent stroke and transient ischemic attack (1"The Gray Sheet" March 27, 2005, p. 29). The firm expects approval by the end of 2006...